Prolactinoma: Pathophysiology, Imaging Features, Diagnosis, and Treatment – A Giant Invasive Pituitary Macroadenoma Case Review
Introduction
Prolactinoma is the most common type of functional pituitary adenoma and represents a critical entity in neuroendocrinology, neuroradiology, and clinical neurosurgery. Despite its generally benign nature, large and invasive prolactinomas can present with dramatic neurological deficits and radiologic findings that mimic aggressive skull base tumors.
This column presents a real-world case of a giant invasive prolactinoma, integrating pathophysiology, epidemiology, clinical presentation, imaging characteristics, differential diagnosis, treatment strategies, and prognosis, based on globally authoritative literature and a classic NEJM imaging case. Special emphasis is placed on MRI interpretation and dopamine agonist treatment response.
Pathophysiology of Prolactinoma
Prolactinomas arise from lactotroph cells of the anterior pituitary gland, characterized by autonomous prolactin secretion. Under normal physiology, prolactin release is tonically inhibited by dopamine via D2 receptors from the hypothalamus.
In prolactinoma:
Dopaminergic inhibition is overridden
Prolactin secretion becomes autonomous
Tumor growth may become expansive and invasive
At a molecular level:
Dysregulation of dopamine D2 receptor signaling
Altered estrogen receptor expression
Increased angiogenesis and cellular proliferation in aggressive tumors
Importantly, giant prolactinomas (>4 cm) may paradoxically present with falsely low serum prolactin levels due to the “hook effect”, a critical diagnostic pitfall.
Epidemiology
Prolactinomas account for 40–60% of all pituitary adenomas
Incidence: ~6–10 per 100,000 population
Female predominance in microadenomas
Male predominance in giant and invasive prolactinomas
Typically diagnosed earlier in women due to menstrual symptoms
Clinical Presentation
Hormonal Effects
Hyperprolactinemia
Hypogonadism
Infertility
Osteopenia or osteoporosis
Neurological Symptoms (Macroadenoma / Giant Prolactinoma)
Severe headache
Visual field defects
Cranial nerve palsies
Hemiparesis (rare but possible)
Hearing disturbances due to skull base invasion
Case Summary
A 33-year-old man presented with:
Severe headache for 6 months
Left-sided hemiparesis
Left-sided hearing impairment
MRI revealed a giant skull–base–invasive pituitary mass measuring 5.6 × 6.9 cm. Initial serum prolactin was reported as 7.3 μg/L, suspiciously low given tumor size—raising concern for a laboratory hook effect.
Imaging Features of Prolactinoma
Figure 1. Pre-treatment MRI (T1-weighted imaging with gadolinium enhancement)
A massive lobulated tumor originating from the sella turcica demonstrates intense heterogeneous enhancement, consistent with a highly vascular pituitary adenoma. There is multidirectional extension:
Suprasellar extension compressing the optic chiasm and elevating the third ventricular floor
Parasellar invasion into both cavernous sinuses with partial encasement of the internal carotid arteries
Infrasellar erosion into the sphenoid sinus
These features are characteristic of an invasive giant prolactinoma rather than a non-functioning adenoma
Figure 2. Post-treatment MRI (T1-weighted imaging with gadolinium enhancement)
Following dopamine agonist therapy, there is dramatic tumor shrinkage, producing the classic “melting sign” of prolactinoma. Mass effect on the optic apparatus and brainstem is markedly relieved. Residual enhancing tissue remains in the sella and right cavernous sinus (red arrows), requiring long-term surveillance
Differential Diagnosis
| Disease | Key Differentiating Features |
|---|---|
| Craniopharyngioma | Cystic, calcified, suprasellar |
| Cushing disease | ACTH-secreting microadenoma |
| Meningioma | Dural tail, homogeneous enhancement |
| Rathke cleft cyst | Non-enhancing cystic lesion |
| Prolactinoma | Dramatic DA response, cavernous sinus invasion |
Diagnosis
Diagnosis of prolactinoma requires:
Serum prolactin measurement (repeat with dilution if giant tumor)
Pituitary MRI with contrast
Assessment for hypopituitarism
Exclusion of secondary hyperprolactinemia
Key diagnostic pearl:
In giant prolactinomas, unexpectedly normal or mildly elevated prolactin levels should raise suspicion for the hook effect.
Treatment
First-Line Therapy
Dopamine Agonists (DA):
Cabergoline (preferred)
Bromocriptine
Effects:
Normalization of prolactin
Tumor volume reduction (often >50%)
Symptom relief
Surgery
Indications:
DA resistance
Acute visual compromise
CSF leak
Radiotherapy
Reserved for refractory or recurrent disease
Prognosis
Excellent with medical therapy
Long-term DA therapy is often required
Recurrence possible after drug withdrawal
Lifelong follow-up recommended
Quiz
Question 1. A giant pituitary mass shows dramatic shrinkage after dopamine agonist therapy. What is the most likely diagnosis?
A. Craniopharyngioma
B. Cushing's disease
C. Meningioma
D. Prolactinoma
E. Rathke cleft cyst
Answer: D. Explanation: Dramatic DA-induced shrinkage is pathognomonic for prolactinoma.
Question 2. Why can serum prolactin be falsely low in giant prolactinomas?
A. Hormone degradation
B. Lab contamination
C. Hook effect
D. Estrogen deficiency
E. Dopamine excess
Answer: C
Question 3. Which MRI feature most strongly supports prolactinoma?
A. Calcification
B. Cystic lesion
C. Dural tail
D. Cavernous sinus invasion with dramatic DA response
E. Ring enhancement
Answer: D
References
M. Molitch, “Diagnosis and Treatment of Pituitary Adenomas,” N Engl J Med, vol. 382, no. 10, pp. 937–950, 2020.
E. Melmed et al., “Pituitary Tumors,” Lancet, vol. 397, pp. 111–124, 2021.
J. Schlechte, “Clinical Practice: Prolactinoma,” N Engl J Med, vol. 349, pp. 2035–2041.
A. Freda et al., “Pitfalls in Prolactin Measurement,” J Clin Endocrinol Metab, vol. 84, pp. 485–488.
R. Shimon, “Giant Prolactinomas,” Endocrine, vol. 64, pp. 225–234, 2019.
R. Thapar et al., “Pituitary Imaging,” Radiographics, vol. 35, pp. 173–193.
NEJM Image in Clinical Medicine, DOI: 10.1056/NEJMicm0906033.
Comments
Post a Comment